S&P 500   4,266.40 (-0.50%)
DOW   33,317.12 (-0.57%)
QQQ   359.69 (+0.40%)
AAPL   173.60 (+1.40%)
MSFT   320.05 (+1.36%)
META   305.32 (+1.70%)
GOOGL   133.62 (+2.11%)
AMZN   129.54 (+1.90%)
TSLA   249.68 (-0.22%)
NVDA   445.68 (+2.46%)
NIO   8.79 (-2.77%)
BABA   86.29 (-0.52%)
AMD   102.41 (-0.40%)
T   14.72 (-2.00%)
F   12.30 (-0.97%)
MU   67.74 (-0.43%)
CGC   0.74 (-5.61%)
GE   108.89 (-1.50%)
DIS   81.54 (+0.60%)
AMC   8.08 (+1.13%)
PFE   33.79 (+1.87%)
PYPL   58.80 (+0.58%)
NFLX   380.13 (+0.67%)
S&P 500   4,266.40 (-0.50%)
DOW   33,317.12 (-0.57%)
QQQ   359.69 (+0.40%)
AAPL   173.60 (+1.40%)
MSFT   320.05 (+1.36%)
META   305.32 (+1.70%)
GOOGL   133.62 (+2.11%)
AMZN   129.54 (+1.90%)
TSLA   249.68 (-0.22%)
NVDA   445.68 (+2.46%)
NIO   8.79 (-2.77%)
BABA   86.29 (-0.52%)
AMD   102.41 (-0.40%)
T   14.72 (-2.00%)
F   12.30 (-0.97%)
MU   67.74 (-0.43%)
CGC   0.74 (-5.61%)
GE   108.89 (-1.50%)
DIS   81.54 (+0.60%)
AMC   8.08 (+1.13%)
PFE   33.79 (+1.87%)
PYPL   58.80 (+0.58%)
NFLX   380.13 (+0.67%)
S&P 500   4,266.40 (-0.50%)
DOW   33,317.12 (-0.57%)
QQQ   359.69 (+0.40%)
AAPL   173.60 (+1.40%)
MSFT   320.05 (+1.36%)
META   305.32 (+1.70%)
GOOGL   133.62 (+2.11%)
AMZN   129.54 (+1.90%)
TSLA   249.68 (-0.22%)
NVDA   445.68 (+2.46%)
NIO   8.79 (-2.77%)
BABA   86.29 (-0.52%)
AMD   102.41 (-0.40%)
T   14.72 (-2.00%)
F   12.30 (-0.97%)
MU   67.74 (-0.43%)
CGC   0.74 (-5.61%)
GE   108.89 (-1.50%)
DIS   81.54 (+0.60%)
AMC   8.08 (+1.13%)
PFE   33.79 (+1.87%)
PYPL   58.80 (+0.58%)
NFLX   380.13 (+0.67%)
S&P 500   4,266.40 (-0.50%)
DOW   33,317.12 (-0.57%)
QQQ   359.69 (+0.40%)
AAPL   173.60 (+1.40%)
MSFT   320.05 (+1.36%)
META   305.32 (+1.70%)
GOOGL   133.62 (+2.11%)
AMZN   129.54 (+1.90%)
TSLA   249.68 (-0.22%)
NVDA   445.68 (+2.46%)
NIO   8.79 (-2.77%)
BABA   86.29 (-0.52%)
AMD   102.41 (-0.40%)
T   14.72 (-2.00%)
F   12.30 (-0.97%)
MU   67.74 (-0.43%)
CGC   0.74 (-5.61%)
GE   108.89 (-1.50%)
DIS   81.54 (+0.60%)
AMC   8.08 (+1.13%)
PFE   33.79 (+1.87%)
PYPL   58.80 (+0.58%)
NFLX   380.13 (+0.67%)
NASDAQ:AXSM

Axsome Therapeutics (AXSM) Stock Forecast, Price & News

$67.23
-2.66 (-3.81%)
(As of 02:20 PM ET)
Compare
Today's Range
$66.90
$70.00
50-Day Range
$69.25
$82.21
52-Week Range
$38.87
$91.29
Volume
632,332 shs
Average Volume
863,986 shs
Market Capitalization
$3.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$104.45

Axsome Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
53.2% Upside
$104.45 Price Target
Short Interest
Bearish
17.21% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
0.49mentions of Axsome Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$828,293 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.04) to ($2.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars

Medical Sector

77th out of 969 stocks

Pharmaceutical Preparations Industry

20th out of 453 stocks


AXSM stock logo

About Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

AXSM Price History

AXSM Stock News Headlines

Axsome Therapeutics (NASDAQ:AXSM) Stock Price Down 3.7%
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Axsome Therapeutics (NASDAQ:AXSM) Receives Buy Rating from Mizuho
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
This Promising Biotech Is Just Right for a Covered-Call Play
Q2 2023 Axsome Therapeutics Inc Earnings Call
See More Headlines
Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Company Calendar

Last Earnings
8/07/2023
Today
10/02/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXSM
Employees
422
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$104.45
High Stock Price Forecast
$180.00
Low Stock Price Forecast
$81.00
Forecasted Upside/Downside
+49.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

Net Income
$-187,130,000.00
Net Margins
-101.07%
Pretax Margin
-100.00%

Debt

Sales & Book Value

Annual Sales
$50.04 million
Book Value
$2.52 per share

Miscellaneous

Free Float
35,629,000
Market Cap
$3.30 billion
Optionable
Optionable
Beta
1.87
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Herriot Tabuteau M.D. (Age 55)
    Founder, Chairman, CEO & Pres
    Comp: $1.32M
  • Mr. Nick Pizzie CPAMr. Nick Pizzie CPA (Age 48)
    M.B.A., Chief Financial Officer
    Comp: $732.94k
  • Mr. Mark L. Jacobson (Age 40)
    COO & Sec.
    Comp: $784.66k
  • Mr. Hunter Murdock Esq. (Age 43)
    Gen. Counsel & Sec.
    Comp: $735.39k
  • Dr. Amanda Jones Pharm.D. (Age 40)
    Sr. VP of Clinical Devel.
  • Ms. Lori Englebert M.B.A. (Age 45)
    Exec. VP of Commercial & Bus. Devel.
  • Joseph Debrah-Afful CPA
    M.B.A., Director of Fin.













AXSM Stock - Frequently Asked Questions

Should I buy or sell Axsome Therapeutics stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AXSM shares.
View AXSM analyst ratings
or view top-rated stocks.

What is Axsome Therapeutics' stock price forecast for 2023?

11 equities research analysts have issued 1-year price targets for Axsome Therapeutics' shares. Their AXSM share price forecasts range from $81.00 to $180.00. On average, they predict the company's stock price to reach $104.45 in the next year. This suggests a possible upside of 49.5% from the stock's current price.
View analysts price targets for AXSM
or view top-rated stocks among Wall Street analysts.

How have AXSM shares performed in 2023?

Axsome Therapeutics' stock was trading at $77.13 on January 1st, 2023. Since then, AXSM stock has decreased by 9.4% and is now trading at $69.89.
View the best growth stocks for 2023 here
.

When is Axsome Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our AXSM earnings forecast
.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) posted its quarterly earnings data on Monday, August, 7th. The company reported ($1.00) earnings per share for the quarter, topping the consensus estimate of ($1.24) by $0.24. The company earned $46.70 million during the quarter, compared to the consensus estimate of $40.19 million. Axsome Therapeutics had a negative net margin of 101.07% and a negative trailing twelve-month return on equity of 92.39%.

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

How do I buy shares of Axsome Therapeutics?

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $69.89.

How much money does Axsome Therapeutics make?

Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $3.30 billion and generates $50.04 million in revenue each year. The company earns $-187,130,000.00 in net income (profit) each year or ($4.28) on an earnings per share basis.

How many employees does Axsome Therapeutics have?

The company employs 422 workers across the globe.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for the company is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245.

This page (NASDAQ:AXSM) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -